SAN FRANCISCO -- A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of plasma concentrations compared with twice-yearly subcutaneous ...
The authors wish to acknowledge the research contribution of Katarzyna Odgers who is lead author on the meta-analysis cited. Bronwyn Graham receives funding from the Australian Research Council.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results